Created by Schengatto

BioArctic AB (publ) (BRCTF)

Healthcare
Biotechnology
Sweden
Yahoo Finance  •  Trading View  •  Company site
Price
$30.25
▼ -5.04 (-14.28%)
Market Cap
$2,681,404,928
Shares: 74,241,489
P/E
N/A
P/B: N/A
ROE
N/A
Current Ratio: N/A
Fundamentals Score
9 (NEGATIVE)
Overview
Financials
Valuation
Technical
Governance
News

Company Overview

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

Headquarters: Warfvinges vag 35, Stockholm, 112 51, Sweden  |  Employees: 122  |  Website: bioarctic.se
Key Contacts
IR / Phone: 46 86 95 69 30
Exchange: PNK
Industry: Biotechnology
Quick Financial Snapshot
RevenueN/A
Net IncomeN/A
Free Cash FlowN/A
Book Value / ShareN/A

Balance Sheet & Liquidity

Total LiabilitiesN/A
Total EquityN/A
Debt / EquityN/A
Current RatioN/A
Interest CoverageN/A
Working CapitalN/A

Valuation Metrics

Core multiples and valuation signals — useful to compare vs peers.

P/E (TTM)N/A
Industry P/EN/A
Forward P/EN/A
P/BN/A
Price / SalesN/A
P / FCFN/A
EV / EBITDAN/A
Graham NumberN/A
DCF (placeholder)—
Notes: red items typically indicate expensive multiples relative to fundamentals. Use the "Compare with industry" tool for context.

EPS (Annual)

Financial Performance

Revenue vs Net Income

Free Cash Flow (annual)

Profitability & Efficiency

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROIC N/A
Asset Turnover N/A

Automated Fundamental Signals (Score: 9)

Passed
  • No passed rules available
Failed
  • Price CAGR 3.42%
  • Positive Free Cash Flow
  • DCF valuation (undefined)

Price Chart (Candlestick)

Technical Analysis (Score: 85)

RSI (14)16.66
SMA 5034.45
SMA 20027.37
MACD-0.26
Signal BULLISH
RSI 16.7, SMA trend bullish, momentum 63.7%.

Governance & Management

Governance scores: Audit: N/A | Board: N/A | Compensation: N/A | Shareholder Rights: N/A
Executive Team
NameTitle
Dr. Gunilla Osswald Ph.D. President & CEO (1961)
Dr. Pär Gellerfors Co-Founder, Senior VP of Business Strategy & Director (1947)
Prof. Lars Lannfelt Co-Founder, Senior VP of Medical science & Director (1949)
Mr. Anders Martin-Lof M.B.A., M.Sc. Chief Financial Officer (1971)
Ms. Johanna Fälting Chief R&D Officer and Head of Research & Development (1972)
Mr. Christer Möller VP of Pre-Clinical Development & Chief Scientific Officer (1959)
Mr. Oskar Bosson VP and Head of IR & Communication (1976)
Ms. Emilie Ankarcrona Smith General Counsel and Head of Legal & IP (1981)
Governance data last updated: N/A

Latest News

No news available for this company.

← Back